Target of Interest
Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Application
图: 1 / 3
Ranibizumab Antibody (A02035-40) in ELISA
Standard curve of Ranibizumab Sandwich ELISA. The Ranibizumab Sandwich ELISA assay is developed by using Anti-Ranibizumab Antibody (6C3), mAb, Mouse (GenScript, A02035-40) and Anti-Ranibizumab Antibody (10D12), mAb, Mouse (GenScript, A02036-40) as the capture and detection antibodies, respectively. In this ELISA assay, Anti-Ranibizumab Antibody (10D12), mAb, Mouse (GenScript, A02036-40) was labeled with Biotin. GenScript can provide customized conjugation services for this product per the customer's request. The Sensitivity of detecting Ra... View More
产品信息
A02035-40
产品规格
种属反应
Human
宿主/亚型
Mouse
/ IgG1, lambda
分类
Monoclonal
类型
Antibody
克隆号
6C3
抗原
Ranibizumab
偶联物
Unconjugated
形式
Lyophilized
纯化类型
Protein A
保存液
PBS, pH 7.4
内含物
0.02% sodium azide
保存条件
-20°C or -80°C if preferred
运输条件
Ambient (domestic); Wet ice (international)
产品详细信息
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.Anti-Ranibizumab Antibody (6C3), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ranibizumab.
靶标信息
Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
生物信息学
蛋白别名: Fab-12 variant Y0317; Lucentis; RhuFab
